CD274 and cancer: Finally, besides the anti-CTLA4 and anti-PD1/PD-L1 agents, several other immune-checkpoints are under investigations in order to potentiate the action of reshaping the immune system activity in the tumor setting and to optimize the outcomes of immunotherapy in cancer patients, with drugs acting both as blockers of the inhibitory regulators of the immune system, or as stimulators of the activating pathways.